CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-30 | Kunkel Lori Anne Director | Option exercise | +3,741 | $1.12 | $4K | 45,625 |
| 2026-10-30 | Kunkel Lori Anne Director | Option exercise | +7,300 | $18.30 | $134K | 52,925 |
| 2026-10-30 | Kunkel Lori Anne Director | Option exercise · Stock Option (right to buy) | −3,741 | 0 | ||
| 2026-10-30 | Kunkel Lori Anne Director | Option exercise · Stock Option (right to buy) | −7,300 | 30,582 | ||
| 2026-10-19 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +6,018 | $14.85 | $89K | 44,018 |
| 2026-10-19 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −6,018 | $38.48 | $232K | 38,000 |
| 2026-10-19 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −6,018 | 175,000 | ||
| 2026-10-19 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +5,000 | $2.48 | $12K | 30,000 |
| 2026-10-19 | Collins Helen Louise CHIEF MEDICAL OFFICER | Sale 10b5-1 | −5,000 | $38.47 | $192K | 25,000 |
| 2026-10-19 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 101,268 | ||
| 2026-10-14 | BALL KRISTINE M Director | Grant or award · Stock Option (right to buy) | +23,394 | 23,394 | ||
| 2026-10-01 | Garland J. Scott Director | Option exercise | +13,000 | $15.47 | $201K | 13,000 |
| 2026-10-01 | Garland J. Scott Director | Sale | −13,000 | $46.67 | $607K | 0 |
| 2026-10-01 | Garland J. Scott Director | Option exercise · Stock Option (right to buy) | −13,000 | 46,372 | ||
| 2026-09-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,982 | $14.85 | $59K | 44,018 |
| 2026-09-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −3,535 | $50.03 | $177K | 40,483 |
| 2026-09-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −2,194 | $50.72 | $111K | 38,289 |
| 2026-09-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −289 | $51.49 | $15K | 38,000 |
| 2026-09-17 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −3,982 | 181,018 | ||
| 2026-09-17 | Collins Helen Louise CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +5,000 | $2.48 | $12K | 30,000 |
Page 1 of 37 · 724 trades